Product Profiles: Asthma – Key companies act to maintain dominancePublished by: Datamonitor Published: Jun. 1, 2012 - 114 Pages Table of Contents
AbstractIntroductionAsthma is an established and growing market dominated by key brands. However, competition is growing and generic threats are increasing, such that the market will become more fragmented. A number of pipeline products, notably once-daily ICS/LABA combinations, are expected to address unmet needs and have high clinical and commercial potential. Features and benefits
Advair (GlaxoSmithKline) was the first ICS/LABA combination to launch but is expected to come under threat from generics and increasing competition, but with Phase III trials complete, its follow-on Relovair is on track to become the first once-daily ICS/LABA, which, if achieved, would ensure that the company maintains its market dominance.Several biologics have advanced in the pipeline. Genentech’s lebrikizumab is currently in large Phase III trials looking at exacerbations and AstraZeneca’s tralokinumab and benralizumab are both in Phase II. Biologics could address unmet needs for subsets of uncontrolled patients, but key opinion leaders maintain skepticism over their viability.Despite patent expiries for key ICS/LABA combinations, generics have not yet entered any of the seven major markets. Datamonitor believes that in the next couple of years they will launch as branded generics. Lower price discounts together with patients’ hesitation to switch devices will help the brands resist generic erosion. Your key questions answered
Get full details about this report >> |
|
|
|
About MarketResearch.com
|
||
|
|
On the WEB
1/18/2013 - 32